RBC
SYRE icon

Roble Belko & Company’s Spyre Therapeutics SYRE Stock Holding History

Roble Belko & Company’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-4
Closed -$1K – 350
2019
Q2 		$1K Buy
+4
New +$691 ﹤0.01% 333

Other funds holding SYRE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Roble Belko & Company's SYRE Position: Q3 2019 in Review

Roble Belko & Company sold out of Spyre Therapeutics (SYRE) in Q3 2019, closing a stake of 4 shares — an estimated $1K sold.

Roble Belko & Company first reported a position in SYRE in Q2 2019 and held it in 1 quarter. The position peaked at $1K in Q2 2019. 71 funds tracked by Wall St. Rank hold SYRE as of Q3 2019.

  • Roble Belko & Company reported no remaining Spyre Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Roble Belko & Company sold 4 Spyre Therapeutics shares in Q3 2019, an estimated $1K.
  • Roble Belko & Company first reported a position in Spyre Therapeutics in Q2 2019 and held it in 1 quarter.
  • Roble Belko & Company's Spyre Therapeutics position peaked at $1K in Q2 2019.
  • 71 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2019.

Based on Roble Belko & Company's 13F filing for Q3 2019, filed 13 Nov 2019.